IPP Bureau
World’s first intra nasal vaccine iNCOVACC from Bharat Biotech receives approval
By IPP Bureau - September 07, 2022
iNCOVACC was developed in partnership with Washington University St. Louis, which had designed and developed the recombinant adenoviral vectored constructs and evaluated them in preclinical studies for efficacy
Football sized rare mesenteric tumour removed laparoscopically at the CK Birla Hospital
By IPP Bureau - September 07, 2022
In a rare occurrence worldwide, the CK Birla Hospital® treats 32-year-old woman for a giant mesenteric tumour via complex laparoscopic surgery
Lupin and DKSH sign licensing and supply agreement to market five biosimilar candidates in the Philippines
By IPP Bureau - September 07, 2022
Lupin’s subsidiary in Philippines, Multicare Pharmaceuticals, will file for marketing approval and be responsible for distribution and commercialization of the biosimilars once approved.
Mandaviya virtually lays Foundation Stone of NCDC branches in 6 states
By IPP Bureau - September 07, 2022
NCDC branches in States/UTs will provide a boost to Public Health Infrastructurewith prompt surveillance, rapid detection and timely monitoring of diseases enabling Early Interventions
Lonza and Touchlight collaborate on end-to-end mRNA offering
By IPP Bureau - September 07, 2022
Under the terms of the agreement, Lonza can now provide its customers with seamless access to Touchlight’s enzymatic DNA technology
Boehringer Ingelheim InPedILD Phase III trial showed encouraging results for both primary endpoints
By IPP Bureau - September 06, 2022
New data from Boehringer Ingelheim support the potential use of nintedanib in children and adolescents with fibrosing interstitial lung disease
Artemis Hospitals opens new centre Daffodils by Artemis in Jaipur
By IPP Bureau - September 06, 2022
Daffodils by Artemis is a premiere luxury birthing centre offering mother and child care services.
InnoCare announces priority review of Orelabrutinib for the treatment of R/R MZL by NMPA
By IPP Bureau - September 06, 2022
Orelabrutinib is a highly selective BTK inhibitor developed by InnoCare for the treatment of cancers and autoimmune diseases.
Balaxi Pharma to issue Rs. 49.61 crore Equity Shares/Warrants
By IPP Bureau - September 06, 2022
Proceeds from the proposed issue will be utilized to part finance Balaxi’s planned EU GMP-compliant manufacturing facility for Oral Solid Dosages and Liquid Injectables at TSIIC Pharma Formulations SEZ
Aurionpro acquires US based startup Hello Patients
By IPP Bureau - September 06, 2022
Hello Patients provides healthcare billing and patients’ management solution
AstraZeneca partners with Alveofit to scale up the diagnosis and treatment of lung diseases in India
By IPP Bureau - September 05, 2022
This partnership aims to embed latest technological advancements in diagnosing and managing lung disorders and associated non-communicable diseases like asthma, pulmonary fibrosis and COPD.
Pfizer and BioNTech receive positive CHMP opinion for Omicron BA.1-adapted bivalent COVID-19 vaccine booster in EU
By IPP Bureau - September 05, 2022
CHMP recommendation based on safety, tolerability, and immunogenicity data from a Phase 2/3 trial of the Omicron BA.1-adapted bivalent vaccine
Yingli Pharma announces first patient dosed in Phase 2 Trial of Linperlisib for peripheral T Cell Lymphoma
By IPP Bureau - September 05, 2022
Phase 2 study to assess efficacy and safety of once daily linperlisib in patients with advanced peripheral T/NK cell lymphoma
Dr. Mandaviya emphasizes on ‘Jan Bhagidari’ to popularise organ donation
By IPP Bureau - September 05, 2022
The purpose of the conclave was to discuss the present situation of body-organ-eye donation in India and find solutions to the challenges ahead in future
Ginkgo Bioworks appoints Dr. Behzad Mahdavi as Sr. VP of Biopharma Manufacturing & Life Science Tools
By IPP Bureau - September 03, 2022
Dr. Mahdavi will lead Ginkgo's commercial efforts in the growing areas of bio-reagents, cell and gene therapies and new biopharmaceutical modalities.
